Company attributes
Other attributes
Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs.
The company focuses on developing, manufacturing and commercializing novel cancer immunotherapies based on tumor infiltrating lymphocytes, which is a personalized approach for patients to receive a one-time treatment with their own expanded and rejuvenated T-cells to treat cancer.
Building from the initial academic process at NCI, the company's proprietary Iovance TIL technology platform introduces a second-generation process (Gen 2) with manufacturing and logistical efficiencies aimed at further optimizing treatment, decreasing production time and streamlining distribution processes.
The company's T cell-based immunotherapy technology platform is potentially applicable to many tumor types and blood cancers. Its lead TIL product candidate, lifileucel, is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive clinical efficacy following one-time administration for metastatic melanoma and cervical cancer.
For blood cancers, the company is investigating a peripheral blood lymphocyte therapy that consists of a non-genetically modified, polyclonal T cell product which is manufactured from a patient’s blood sample using a nine-day process.
